SUPPORTING INFORMATION

Stereospecific [3+2] Cycloaddition of 1,2-Cyclopropanated Sugars and Ketones Catalyzed by SnCl₄: an Efficient Synthesis of Multi-Substituted Perhydrofuro[2,3-*b*]furans and Perhydrofuro[2,3-*b*]pyrans

Xiaofeng Ma, a Jichao Zhang, a Qin Tang, a Jun Ke, a Wei Zou, b and Huawu Shao a

^a Natural Products Research Center, Chengdu Institute of Biology,

Chinese Academy of Sciences, Chengdu, 610041, China

^b Institute for Biological Sciences, National Research Council of Canada, 100 Sussex Drive, Ottawa, Ontario K1A 0R6.

*Correspondence author: E-mail: shaohw@cib.ac.cn

Fax: (+86) 28-82890288

Table of contents

General Information	S3
Preparation of Starting Materials	S3
Synthesis of Perhydrofuro[2,3-b]pyran and Bis-THF Derivatives	S4-S19
Selected IR Data for the Products	S19-S20
The Stereochemistry of Products	S20-S21

1. General

All reactions sensitive to air or moisture were carried out under nitrogen or argon atmosphere with anhydrous solvents. All reagents were purchased from commercial suppliers and used without further purification unless otherwise noted. Thin-layer chromatography was performed using silica gel GF254 precoated plates (0.20–0.25 mm thickness) with a fluorescent indicator. Visualization on TLC was achieved by UV light (254 nm) and a typical TLC indication solution (10% sulfuric acid / ethanol solution). Column chromatography was performed on silica gel 90, 200-300 mesh. Optical rotations were measured with a Perkin Elmer M341 Digital Polarimeter. 1 H and 13 C NMR (600 and 150 MHz, respectively) spectra were recorded on a Bruker Avance 600 spectrometer. 1H NMR chemical shifts are reported in ppm (δ) relative to tetramethylsilane (TMS) with the solvent resonance employed as the internal standard (CDCl₃, δ 7.26 ppm; CD₃COCD₃, δ 2.05 ppm). Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constants (Hz) and integration. 13 C NMR chemical shifts are reported in ppm from tetramethylsilane (TMS) with the solvent resonance as the internal standard (CDCl₃, δ 77.0 ppm; CD₃COCD₃, δ 39.5). HRESIMS spectra were recorded on BioTOFQ.

Preparation of Starting Materials:

1-*C*-Acetyl-3,4,6-tri-*O*-benzyl-1,2-cyclopropane-1,2-deoxy-α-D-galactopyranose (**1a**), 1-*C*-Acetyl-3,4,6-tri-*O*-benzyl-1,2-cyclopropane-1,2-deoxy-α-D-glucopyranose (**1b**) and 1-*C*-Acetyl-3,4-Di-*O*-benzyl-1,2-cyclopropane-1,2-deoxy-α-D-lyxofuranose (**1c**) were obtained as our previously reported methods.

General procedure for SnCl₄-catalyzed transformation for cyclopropanated sugars to per-substituted perhydrofuro[2,3-b]pyran and furan derivatives.

Method A: Under an argon atmosphere, $SnCl_4$ (2.3 μ L, 0.02 mmol) in 0.5 mL CH_2Cl_2 was added to a mixture of 4 Å M.S. (50 mg), cyclopropanated sugars 1 (0.1 mmol) and ketones 2 (0.4 mmol)

in 0.5 mL CH_2Cl_2 . The solution was stirred at 0 °C to 4 °C until the reaction was completed as detected by TLC. Then the reaction was quenched with a vigorously stirred solution of saturated aqueous NaHCO₃ (10 mL), and extracted with CH_2Cl_2 (3 × 20 mL). The combined organic phases were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (ethyl acetate/ petroleum ether = 1:10 to 1:6) to afford products **3** as a single diastereoisomer.

Method B: Under an argon atmosphere, SnCl₄ (2.3 μL, 0.02 mmol) in 0.5 mL CH₂Cl₂ was added to a mixture of 4 \acute{A} M.S. (50 mg), cyclopropanated sugars **1** (0.1 mmol) and ketones **2** (1.0 mmol) in 0.5 mL CH₂Cl₂. The solution was stirred at 0 °C to 4 °C until the reaction was completed as detected by TLC. Then the reaction was quenched with a vigorously stirred solution of saturated aqueous NaHCO₃ (10 mL), and extracted with CH₂Cl₂ (3 × 20 mL). The combined organic phases were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (ethyl acetate/ petroleum ether = 1:6) to afford products **3** as a single diastereoisomer.

Experimental Procedures and Spectral Data

(2S,3S,3aR,4R,5R,6R,7aS)-3-acetyl-4,5-bis(benzyloxy)-6-[(benzyloxy)methyl]-2-methyl-2-phenylhexahydrofuro[2,3-b]pyran (3aa)

Compound **3aa** was prepared according to Method A using (47.3 mg, 0.1 mmol) cyclopropanated sugars **1a** and ketone **2a** (47.2 μ L, 0.4 mmol), after purified by column chromatography on silica gel (ethyl acetate/ petroleum ether = 1:9), afforded the desired product **3aa** (47.4 mg, 0.080 mmol, 80%) as colorless syrup. [α]_D²⁰ +65.9 (c 0.14, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.42 (d, J = 7.9 Hz, 2H), 7.37 – 7.25 (m, 17H), 5.85 (d, J = 4.3 Hz, 1H), 4.80 (d, J = 11.7 Hz, 1H), 4.54 (d, J = 11.8 Hz, 1H), 4.51 (d, J = 11.9 Hz, 1H), 4.46 (d, J = 11.7 Hz, 1H), 4.38 (d, J = 11.8 Hz, 1H), 4.06 (t, J = 6.6 Hz, 1H), 3.92 (d, J = 11.8 Hz, 1H), 3.81 (s, 1H), 3.67 (d, J = 6.6 Hz, 2H), 3.48 (d, J = 1.7 Hz, 1H), 3.09 (dd, J = 10.0, 2.1 Hz, 1H), 2.78 (ddd, J = 10.1, 4.2, 2.0 Hz, 1H), 2.27 (s, 3H),

1.42 (s, 3H); 13 C NMR (150 MHz, CDCl₃) δ 208.1, 148.5, 138.5, 137.9, 137.9, 128.7, 128.5, 128.3, 128.1, 128.0, 127.8, 127.7, 127.6, 126.9, 124.1, 101.2, 82.0, 78.2, 74.0, 73.6, 72.1, 71.4, 70.2, 68.6, 62.8, 43.9, 32.1, 29.7, 27.5; ESI-HRMS: m/z calcd for $C_{38}H_{40}NaO_{6}[M+Na]^{+}$: 615.2717; found: 615.2714.

(2S,3S,3aR,4R,5R,6R,7aS)-3-acetyl-4,5-bis(benzyloxy)-6-[(benzyloxy)methyl]-

2-methyl-2-(4-tolyl)hexahydrofuro[2,3-b]pyran (3ab)

Compound **3ab** was prepared according to Method A using (47.3 mg, 0.1 mmol) cyclopropanated sugars **1a** and ketone **2b** (56.2 μ L, 0.4 mmol), after purified by column chromatography on silica gel (ethyl acetate/ petroleum ether = 1:9), afforded the desired product **3ab** (53.4 mg, 0.088 mmol, 88%) as colorless syrup. [α]_D²⁰ +68.2 (c 0.24, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.36 – 7.26 (m, 15H), 7.12 (d, J = 7.9 Hz, 2H), 7.09 (s, 2H), 5.84 (d, J = 4.3 Hz, 1H), 4.80 (d, J = 11.7 Hz, 1H), 4.55 (d, J = 11.7 Hz, 1H), 4.52 (d, J = 11.7 Hz, 1H), 4.47 (d, J = 11.7 Hz, 1H), 4.39 (d, J = 11.8 Hz, 1H), 4.06 (t, J = 6.7 Hz, 1H), 3.97 (d, J = 11.8 Hz, 1H), 3.82 (s, 1H), 3.67 (d, J = 6.5 Hz, 2H), 3.47 (s, 1H), 3.11 (dd, J = 9.8, 1.3 Hz, 1H), 2.79 – 2.77 (m, 1H), 2.36 (s, 3H), 2.26 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 208.2, 145.5, 138.5, 137.9, 137.8, 136.4, 129.3, 128.5, 128.4, 128.3, 128.1, 128.0, 127.8, 127.7, 127.6, 124.0, 101.1, 82.1, 78.1, 73.9, 73.6, 72.1, 71.3, 70.2, 68.6, 62.9, 43.9, 32.1, 29.7, 27.5, 21.0; ESI-HRMS: m/z calcd for C₃₉H₄₂NaO₆[M+Na]⁺: 629.2874; found: 629.2862.

(2S,3S,3aR,4R,5R,6R,7aS)-3-acetyl-4,5-bis(benzyloxy)-6-[(benzyloxy)methyl]-

2-methyl-2-(4-chlorophenyl)hexahydrofuro[2,3-b]pyran (3ac)

Compound **3ac** was prepared according to Method A using (47.3 mg, 0.1 mmol) cyclopropanated sugars **1a** and ketone **2c** (53.5 μ L, 0.4 mmol), after purified by column chromatography on silica gel (ethyl acetate/ petroleum ether = 1:9), afforded the desired product **3ac** (52.0 mg, 0.083 mmol,

83%) as colorless syrup. $[\alpha]_D^{20} + 62.4$ (c 0.19, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.38 – 7.22 (m, 17H), 7.07 (d, J = 7.4 Hz, 2H), 5.80 (d, J = 4.4 Hz, 1H), 4.81 (d, J = 11.7 Hz, 1H), 4.56 (d, J = 11.7 Hz, 1H), 4.52 (d, J = 11.7 Hz, 1H), 4.48 (d, J = 11.8 Hz, 1H), 4.44 (d, J = 12.1 Hz, 1H), 4.01 (dd, J = 16.0, 9.2 Hz, 2H), 3.86 (s, 1H), 3.67 (d, J = 6.2 Hz, 2H), 3.30 (d, J = 1.7 Hz, 1H), 3.02 (dd, J = 10.0, 1.7 Hz, 1H), 2.76 (ddd, J = 6.4, 4.0, 2.0 Hz, 1H), 2.25 (s, 3H), 1.36 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 207.7, 146.8, 138.4, 137.8, 137.5, 132.6, 128.8, 128.5, 128.5, 128.3, 128.1, 128.0, 128.0, 127.9, 127.8, 127.7, 125.5, 101.0, 81.6, 77.5, 74.0, 73.7, 72.2, 70.7, 69.9, 68.5, 62.9, 43.9, 31.9, 29.7, 27.2; ESI-HRMS: m/z calcd for C₃₈H₃₉ClNaO₆[M+Na][†]: 649.2333; found: 649.2325.

(2S,3S,3aR,4R,5R,6R,7aS)-3-acetyl-4,5-bis(benzyloxy)-6-[(benzyloxy)methyl]-2-methyl-2-(4-bromophenyl)hexahydrofuro[2,3-b]pyran (3ad)

Compound **3ad** was prepared according to Method A using (47.3 mg, 0.1 mmol) cyclopropanated sugars **1a** and ketone **2d** (81.2 mg , 0.4 mmol), after purified by column chromatography on silica gel (ethyl acetate/ petroleum ether = 1:9), afforded the desired product **3ad** (53.6 mg, 0.080 mmol, 80%) as colorless syrup. [α]_D²⁰ +80.2 (c 0.19, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.40 – 7.25 (m, 15H), 7.20 (d, J = 8.6 Hz, 2H), 7.09 – 7.05 (m, 2H), 5.80 (d, J = 4.4 Hz, 1H), 4.81 (d, J = 11.7 Hz, 1H), 4.57 (d, J = 11.7 Hz, 1H), 4.52 (d, J = 11.8 Hz, 1H), 4.48 (d, J = 11.7 Hz, 1H), 4.44 (d, J = 12.1 Hz, 1H), 4.00 (dd, J = 12.7, 7.7 Hz, 2H), 3.86 (s, 1H), 3.67 (dd, J = 11.7, 5.6 Hz, 2H), 3.29 (d, J = 1.9 Hz, 1H), 3.01 (dd, J = 10.0, 2.1 Hz, 1H), 2.76 (ddd, J = 9.9, 4.3, 2.2 Hz, 1H), 2.28 (s, 3H), 1.38 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 207.7, 147.4, 138.4, 137.8, 137.5, 131.7, 128.5, 128.5, 128.3, 128.1, 128.0, 128.0, 127.9, 127.9, 127.7, 125.8, 120.8, 101.1, 81.6, 77.4, 74.0, 73.7, 72.2, 70.7, 69. 9, 68.5, 62.8, 43.9, 32.0, 29.7, 27.2; ESI-HRMS: m/z calcd for C₃₈H₃₉BrNaO₆[M+Na][†]: 693.1822; found: 693.1848.

(2S,3S,3aR,4R,5R,6R,7aS)-3-acetyl-4,5-bis(benzyloxy)-6-[(benzyloxy)methyl]-2-methyl-2-(4-trifluoromethylphenyl)hexahydrofuro[2,3-b]pyran (3ae)

Compound **3ae** was prepared according to Method A using (47.3 mg, 0.1 mmol) cyclopropanated sugars **1a** and ketone **2e** (76.8 mg, 0.4 mmol), after purified by column chromatography on silica gel (ethyl acetate/ petroleum ether = 1: 9), afforded the desired product **3ae** (42.9 mg, 0.065 mmol, 65%) as colorless syrup. [α]_D²⁰ +61.4 (c 0.24, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.52 (d, J = 8.2 Hz, 2H), 7.42 (d, J = 8.2 Hz, 2H), 7.38 – 7.34 (m, 2H), 7.31 (dd, J = 10.1, 5.9 Hz, 8H), 7.24 – 7.19 (m, 3H), 7.04 (d, J = 6.5 Hz, 2H), 5.82 (d, J = 4.4 Hz, 1H), 4.82 (d, J = 11.7 Hz, 1H), 4.57 (d, J = 11.7 Hz, 1H), 4.53 (d, J = 11.7 Hz, 1H), 4.48 (d, J = 11.7 Hz, 1H), 4.43 (d, J = 12.2 Hz, 1H), 4.02 (t, J = 6.6 Hz, 1H), 3.97 (d, J = 12.2 Hz, 1H), 3.87 (s, 1H), 3.68 (d, J = 6.4 Hz, 2H), 3.29 (d, J = 1.8 Hz, 1H), 2.95 (dd, J = 10.0, 2.1 Hz, 1H), 2.80 – 2.74 (m, 1H), 2.28 (s, 3H), 1.38 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 207.6, 152.1, 138.3, 137.8, 137.4, 128.9, 128.6, 128.5, 128.4, 128.3, 128.1, 128.1, 128.0, 127.9, 127.8, 127.7, 125.7, 124.4, 101.1, 81.6, 77.3, 74.1, 73.7, 72.2, 70.5, 69.8, 68.5, 62.7, 44.0, 32.0, 29.7, 27.3; ESI-HRMS: m/z calcd for C₃₉H₃₉F₃NaO₆[M+Na]⁺: 683.2591; found: 683.2604.

(2S,3S,3aR,4R,5R,6R,7aS)-3-acetyl-4,5-bis(benzyloxy)-6-[(benzyloxy)methyl]-2-ethyl-2-phenylhexahydrofuro[2,3-b]pyran (3af)

Compound **3af** was prepared according to Method A using (47.3 mg, 0.1 mmol) cyclopropanated sugars **1a** and ketone **2f** (54.3 μ L, 0.4 mmol), after purified by column chromatography on silica gel (ethyl acetate/ petroleum ether = 1:9), afforded the desired product **3af** (47.4 mg, 0.080 mmol, 80%) as colorless syrup. [α]_D²⁰ +51.5 (c 0.20, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.39 – 7.27 (m, 13H), 7.25 – 7.22 (m, 4H), 7.04 (s, 2H), 5.82 (d, J = 4.3 Hz, 1H), 4.80 (d, J = 11.7 Hz, 1H), 4.53 (d, J = 11.7 Hz, 1H), 4.50 (s, 1H), 4.46 (d, J = 11.7 Hz, 1H), 4.33 (d, J = 11.7 Hz, 1H), 4.09 (t, J = 6.6 Hz, 1H), 3.86 (d, J = 11.7 Hz, 1H), 3.79 (s, 1H), 3.69 – 3.65 (m, 2H), 3.49 (s, 1H), 3.08 (d, J = 10.4 Hz, 1H), 2.72 (dd, J = 10.3, 4.3 Hz, 1H), 2.30 (s, 3H), 0.88 (t, J = 5.8 Hz, 2H), 0.60 (t, J =

7.2 Hz, 3H); 13 C NMR (150 MHz, CDCl₃) δ 208.5, 146.1, 138.5, 137.9, 137.7, 128.4, 128.3, 128.1, 128.1, 127.9, 127.8, 127.7, 127.6, 126.7, 124.8, 101.5, 84.8, 78.3, 74.0, 73.7, 72.1, 71.5, 70.2, 68.7, 63.6, 43.6, 32.4, 31.4, 29.7, 8.4; ESI-HRMS: m/z calcd for $C_{39}H_{42}NaO_{6}[M+Na]^{+}$: 629.2874; found: 629.2854.

(2S, 3S, 3aR, 4R, 5R, 6R, 7aS) - 3 - acetyl - 4, 5 - bis(benzyloxy) - 6 - [(benzyloxy)methyl] - (benzyloxy)methyl] - (benzyloxy)methyl - (benzyloxy)methyl] - (benzyloxy)methyl - (benzylo

2-methyl-2-(furan-2-yl)hexahydrofuro[2,3-b]pyran (3ag)

Compound **3ag** was prepared according to Method A using (47.3 mg, 0.1 mmol) cyclopropanated sugars **1a** and ketone **2g** (44.5 mg, 0.4 mmol), after purified by column chromatography on silica gel (ethyl acetate/ petroleum ether = 1:9), afforded the desired product **3ag** (46.0 mg, 0.079 mmol, 79%) as colorless syrup. [α]_D²⁰ +88.0 (c 0.14, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.35 – 7.24 (m, 16H), 6.28 (dd, J = 3.1, 1.8 Hz, 1H), 6.19 (d, J = 3.2 Hz, 1H), 5.65 (d, J = 4.5 Hz, 1H), 4.85 (d, J = 11.7 Hz, 1H), 4.60 (d, J = 11.7 Hz, 2H), 4.49 (d, J = 11.8 Hz, 1H), 4.46 (d, J = 11.8 Hz, 1H), 4.26 (d, J = 12.0 Hz, 1H), 4.06 (t, J = 6.8 Hz, 1H), 3.96 (s, 1H), 3.68 (t, J = 8.6 Hz, 1H), 3.63 (dd, J = 9.0, 5.5 Hz, 1H), 3.55 (s, 1H), 3.48 (dd, J = 9.7, 1.9 Hz, 1H), 2.90 – 2.85 (m, 1H), 2.12 (s, 3H), 1.42 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 207.0, 157.7, 142.1, 138.5, 138.0, 137.9, 128.5, 128.4, 128.3, 128.0, 127.8, 127.8, 127.6, 110.3, 105.3, 100.9, 78.5, 77.7, 73.9, 73.6, 72.1, 71.1, 70.1, 68.4, 60.4, 43.1, 31.9, 29.7, 23.0; ESI-HRMS: m/z calcd for C₃₆H₃₈NaO₇[M+Na]⁺: 605.2510; found: 605.2516.

Spirocyclic compound 3ah

Compound **3ah** was prepared according to Method A using (47.3 mg, 0.1 mmol) cyclopropanated sugars **1a** and ketone **2h** (64.5 mg, 0.4 mmol), after purified by column chromatography on silica gel (ethyl acetate/ petroleum ether = 1:10), afforded the desired product **3ah** (45.0 mg, 0.071 mmol, 71%) as light red syrup. [α]_D²⁰ +163.0 (c 0.32, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.60

(d, J = 7.5 Hz, 1H), 7.52 (t, J = 7.7 Hz, 1H), 7.35 - 7.29 (m, 15H), 6.83 (t, J = 7.4 Hz, 1H), 6.74 (d, J = 8.3 Hz, 1H), 5.99 (d, J = 4.5 Hz, 1H), 4.89 (d, J = 11.6 Hz, 1H), 4.78 (d, J = 11.7 Hz, 1H), 4.62 (d, J = 11.6 Hz, 1H), 4.59 (d, J = 11.7 Hz, 1H), 4.53 - 4.49 (m, 1H), 4.46 (d, J = 11.9 Hz, 1H), 4.28 (d, J = 8.4 Hz, 1H), 4.18 (t, J = 6.5 Hz, 1H), 4.04 (s, 1H), 3.68 - 3.60 (m, 2H), 3.46 (d, J = 2.5 Hz, 1H), 3.16 - 3.11 (m, 1H), 2.76 (s, 3H), 1.92 (s, 3H); 1.92 (s, 3H); 1.92 NMR (150 MHz, CDCl₃) 1.92 204.3, 1.98.6, 1.98.6, 1.98.8, 1.98.6, 1.98.8, 1.98.

Spirocyclic compound 3ai

Compound **3ai** was prepared according to Method A using (47.3 mg, 0.1 mmol) cyclopropanated sugars **1a** and ketone **2i** (41.9 μ L, 0.4 mmol), after purified by column chromatography on silica gel (ethyl acetate/ petroleum ether = 1:9), afforded the desired product **3ai** (50.2 mg, 0.088 mmol, 88%) as colorless syrup. [α]_D²⁰ +56 (c 0.40, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.40 – 7.25 (m, 15H), 5.44 (d, J = 4.4 Hz, 1H), 4.86 (d, J = 11.7 Hz, 1H), 4.67 (d, J = 12.1 Hz, 1H), 4.62 (d, J = 11.7 Hz, 1H), 4.50 (d, J = 11.8 Hz, 1H), 4.47 (d, J = 11.8 Hz, 1H), 4.34 (d, J = 12.1 Hz, 1H), 4.05 (t, J = 5.9 Hz, 1H), 4.01 (s, 1H), 3.73 – 3.63 (m, 2H), 3.35 (dd, J = 9.4, 1.9 Hz, 1H), 2.74 (dt, J = 9.5, 4.0 Hz, 1H), 2.66 (d, J = 3.7 Hz, 1H), 2.12 (s, 3H), 1.60 (dd, J = 16.9, 7.8 Hz, 4H), 1.48 (d, J = 13.0 Hz, 1H), 1.40 (s, 2H), 1.34 (td, J = 12.9, 3.8 Hz, 1H), 1.15 – 1.05 (m, 1H), 0.97 (t, J = 11.3 Hz, 1H); ¹³C NMR (150 MHz, CDCl₃) δ = 207.5, 138.5, 138.0, 137.8, 128.5, 128.4, 128.4, 128.3, 128.1, 128.0, 128.0, 127.8, 127.6, 99.7, 80.5, 78.6, 73.8, 73.6, 72.2, 70.5, 70.0, 68.3, 63.3, 43.8, 40.6, 33.0, 32.2, 25.1, 23.0, 22.2; ESI-HRMS: m/z calcd for C₃₆H₄₂NaO₆[M+Na][†]: 593.2874; found: 593.2873.

(3S,3aR,4R,5R,6R,7aS)-3-acetyl-4,5-bis(benzyloxy)-6-[(benzyloxy)methyl]-

2,2-di-methylhexahydrofuro[2,3-b]pyran (3aj)

Compound **3aj** was prepared according to Method B using (47.3 mg, 0.1 mmol) cyclopropanated sugars **1a** and acetone **2j** (74.2 μ L, 1.0 mmol), after purified by column chromatography on silica gel (ethyl acetate/ petroleum ether = 1: 6), afforded the desired product **3aj** (49.3 mg, 0.093 mmol, 93%) as colorless syrup. [α]_D²⁰ +48.5 (c 0.46, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.39 – 7.27(m, 15H), 5.43 (d, J = 4.4 Hz, 1H), 4.85 (d, J = 11.7 Hz, 1H), 4.68 (d, J = 12.1 Hz, 1H), 4.63 (d, J = 11.7 Hz, 1H), 4.51 (d, J = 11.8 Hz, 1H), 4.48 (d, J = 11.8 Hz, 1H), 4.35 (d, J = 12.1 Hz, 1H), 4.04 (t, J = 6.7 Hz, 1H), 4.01 (s, 1H), 3.70 (t, J = 8.4 Hz, 1H), 3.65 (dd, J = 9.3, 5.9 Hz, 1H), 3.37 (dd, J = 9.2, 1.9 Hz, 1H), 2.84 (dt, J = 9.0, 4.4 Hz, 1H), 2.76 (d, J = 4.3 Hz, 1H), 2.10 (s, 3H), 1.25 (s,3H), 1.07 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 207.0, 138.5, 138.0, 137.8, 128.6, 128.4, 128.4, 128.3, 128.1, 128.0, 127.7, 127.6, 99.6, 79.0, 78.5, 73.8, 73.5, 72.5, 70.5, 70.1, 68.2, 63.0, 44.1, 31.6, 31.3, 24.8; ESI-HRMS: m/z calcd for C₃₃H₃₈NaO₆[M+Na]⁺: 553.2561; found: 553.2551.

(2R,3S,3aR,4R,5R,6R,7aS)-3-acetyl-4,5-bis(benzyloxy)-6-[(benzyloxy)methyl]-2-ethyl-2-methylhexahydrofuro[2,3-b]pyran (3ak)

Compound **3ak** was prepared according to Method A using (47.3 mg, 0.1 mmol) cyclopropanated sugars **1a** and 2-butanone **2k** (36.2 μ L, 0.4 mmol), after purified by column chromatography on silica gel (ethyl acetate/ petroleum ether = 1:6), afforded the desired product **3ak** (44.1 mg, 0.081 mmol, 81%) as colorless syrup. [α]_D²⁰ +40.9 (c 0.25, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.39 - 7.27 (m,15H), 5.45 (d, J = 4.5 Hz, 1H), 4.86 (d, J = 11.7 Hz, 1H), 4.67 (d, J = 12.2 Hz, 1H), 4.63 (d, J = 11.7 Hz, 1H), 4.48 (q, J = 11.9 Hz, 3H), 4.33 (d, J = 12.2 Hz, 1H), 4.01 (t, J = 4.8 Hz, 2H), 3.68 (t, J = 8.5 Hz, 1H), 3.63 (dd, J = 9.1, 5.6 Hz, 1H), 3.34 (dd, J = 9.5, 1.7 Hz, 1H), 2.82 (dt, J = 9.4, 4.2 Hz,1H), 2.76 (d, J = 3.6 Hz, 1H), 2.10 (s, 3H), 1.50 (dt, J = 14.8, 7.3 Hz, 1H), 1.43 (td, J = 14.7, 7.3 Hz, 1H), 1.02 (s, 3H), 0.87 (dt, J = 14.4, 6.9 Hz, 2H), 0.79 (t, J = 7.4 Hz, 3H); ¹³C NMR (151 MHz, CDCl₃) δ 207.5, 138.5, 138.0, 137.9, 128.6, 128.4, 128.4, 128.3, 128.1, 128.0, 127.8, 127.6, 100.0, 81.3, 78.2, 73.8, 73.6, 72.2, 70.3, 69.9, 68.3, 61.0, 43.7, 36.4, 31.5, 29.7, 21.9, 8.7; ESI-HRMS: m/z calcd for C₃₄H₄₀NaO₆[M+Na][†]: 567.2717; found: 567.2708.

(2R,3S,3aR,4R,5R,6R,7aS)-3-acetyl-4,5-bis(benzyloxy)-6-[(benzyloxy)methyl]-

2-i-butyl-2-methylhexahydrofuro[2,3-b]pyran (3al)

Compound **3al** was prepared according to Method A using (47.3 mg, 0.1 mmol) cyclopropanated sugars **1a** and **2l** (50.5 µL, 0.4 mmol), after purified by column chromatography on silica gel (ethyl acetate/ petroleum ether = 1:6), afforded the desired product **3al** (50.4 mg, 0.088 mmol, 88%) as colorless syrup. [α]_D²⁰ +54.2 (c 0.24, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.40 – 7.28 (m, 15H), 5.41 (d, J = 4.2 Hz, 1H), 4.86 (d, J = 11.7 Hz, 1H), 4.67 (d, J = 12.2 Hz, 1H), 4.63 (d, J = 11.7 Hz, 1H), 4.51 (d, J = 11.8 Hz, 1H), 4.47 (d, J = 11.7 Hz, 1H), 4.33 (d, J = 12.2 Hz, 1H), 3.99 (dd, J = 13.8, 7.3 Hz, 2H), 3.70 (t, J = 8.6 Hz, 1H), 3.63 (dd, J = 9.1, 5.5 Hz, 1H), 3.34 (d, J = 9.6 Hz, 1H), 2.78 (dd, J = 9.0, 4.3 Hz, 1H), 2.72 (d, J = 3.2 Hz, 1H), 2.09 (s, 3H), 1.74 – 1.65 (m, 1H), 1.41 (dd, J = 14.3, 4.5 Hz, 1H), 1.20 (dd, J = 14.4, 7.4 Hz, 1H), 1.05 (s, 3H), 0.89 (d, J = 6.5 Hz, 3H), 0.86 (d, J = 6.6 Hz, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 207.4, 138.5, 138.0, 137.8, 128.6, 128.5, 128.4, 128.3, 128.2, 128.0, 127.8, 127.6, 99.8, 81.1, 78.3, 73.9, 73.6, 72.2, 70.3, 69.8, 68.4, 63.3, 52.8, 43.0, 31.6, 24.9, 24.5, 24.1, 22.1; ESI-HRMS: m/z calcd for C₃₆H₄₄NaO₆[M+Na]⁺: 595.3030; found: 595.3022.

(2R,3S,3aR,4R,5R,6R,7aS)-3-acetyl-4,5-bis(benzyloxy)-6-[(benzyloxy)methyl]-

2-cyclopropyl-2-methylhexahydrofuro[2,3-b]pyran (3am)

Compound **3am** was prepared according to Method A using (47.3 mg, 0.1 mmol) cyclopropanated sugars **1a** and **2m** (38.0 μ L, 0.4 mmol), after purified by column chromatography on silica gel (ethyl acetate/ petroleum ether = 1:9), afforded the desired product **3am** (52.3 mg, 0.094 mmol, 94%) as colorless syrup. [α]_D²⁰ +63.6 (c 0.42, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.38 – 7.28 (m, 15H), 5.39 (d, J = 4.5 Hz, 1H), 4.85 (d, J = 11.7 Hz, 1H), 4.68 (d, J = 12.2 Hz, 1H), 4.62 (d, J = 11.7 Hz, 1H), 4.51 (d, J = 11.8 Hz, 1H), 4.47 (d, J = 11.8 Hz, 1H), 4.37 (d, J = 12.1 Hz, 1H), 4.02 – 3.96 (m, 2H), 3.68 (t, J = 8.3 Hz, 1H), 3.66 – 3.61 (m, 1H), 3.40 (d, J = 9.0 Hz, 1H), 3.00 (d,

J = 4.6 Hz, 1H), 2.88 (dt, J = 9.0, 4.6 Hz, 1H), 2.15 (s, 3H), 1.01 (s, 3H), 0.93 – 0.87 (m, 1H), 0.47 – 0.36 (m, 3H), 0.29 – 0.24 (d, J = 5.8 Hz, 1H); ¹³C NMR (150 MHz, CDCl₃) δ 207.0, 138.5, 138.0, 128.5, 128.4, 128.3, 128.3, 128.0, 128.0, 127.9, 127.8, 127.6, 99.1, 79.9, 78.5, 73.7, 73.6, 72.7, 70.6, 70.2, 68.2, 63.8, 43.5, 31.6, 29.7, 23.2, 22.0, 2.5, 1.1; ESI-HRMS: m/z calcd for $C_{35}H_{40}NaO_{6}[M+Na]^{+}$: 579.2717; found: 579.2722.

(2S,3S,3aR,4R,5S,6R,7aS)-3-acetyl-4,5-bis(benzyloxy)-6-[(benzyloxy)methyl]-

2-methyl-2-phenylhexahydrofuro[2,3-b]pyran

Compound **3ba** was prepared according to Method A using (47.3 mg, 0.1 mmol) cyclopropanated sugars **1b** and ketone **2a** (47.2 μ L, 0.4 mmol),, after purified by column chromatography on silica gel (ethyl acetate/ petroleum ether = 1:9), afforded the desired product **3ba** (50.9 mg, 0.086 mmol, 86%) as colorless syrup. [α]_D²⁰ +27.3 (c 0.25, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.51 (d, J = 7.5 Hz, 2H), 7.38 – 7.22 (m, 16H), 7.13 – 7.09 (m, 2H), 5.72 (d, J = 5.4 Hz, 1H), 4.63 (d, J = 12.1 Hz, 1H), 4.59 (t, J = 11.6 Hz, 2H), 4.46 (d, J = 12.1 Hz, 1H), 4.43 (s, 2H), 4.15 – 4.11 (m, 1H), 3.76 (ddd, J = 14.1, 10.6, 4.2 Hz, 2H), 3.64 (ddd, J = 17.4, 13.3, 6.2 Hz, 2H), 3.42 (t, J = 4.9 Hz, 1H), 3.05 (dt, J = 7.6, 5.4 Hz, 1H), 1.92 (s, 3H), 1.42 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 206.8, 146.1, 138.3, 138.2, 137.8, 128.6, 128.5, 128.4, 128.4, 127.9, 127.8, 127.7, 127.6, 127.4, 125.0, 98.8, 83.5, 76.9, 76.4, 73.5, 72.8, 72.6, 72.4, 69.2, 62.6, 45.1, 31.9, 29.7, 24.4. ESI-HRMS: m/z calcd for C₃₈H₄₀NaO₆[M+Na]⁺: 615.2717; found: 615.2731.

$(2S,\!3S,\!3aR,\!4R,\!5S,\!6R,\!7aS) - 3 - acetyl - 4,\!5 - bis(benzyloxy) - 6 - [(benzyloxy)methyl] - (benzyloxy)methyl] - (benzyloxy)methyll - (benzyloxy)methy$

2-methyl-2-(4-tolyl)-hexahydrofuro[2,3-b]pyran (3bb)

Compound **3bb** was prepared according to Method A using (47.3 mg, 0.1 mmol) cyclopropanated sugars **1b** and ketone **2b** (56.2 μ L, 0.4 mmol),, after purified by column chromatography on silica

gel (ethyl acetate/ petroleum ether = 1:9), afforded the desired product **3bb** (51.5 mg, 0.085 mmol, 85%) as colorless syrup. [α]_D²⁰ +63.9 (c 0.30, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.42 – 7.28 (m, 10H), 7.25 (dd, J = 7.1, 2.6 Hz, 5H), 7.15 (d, J = 8.0 Hz, 2H), 7.14 – 7.09 (m, 2H), 5.71 (d, J = 5.4 Hz, 1H), 4.63 (d, J = 12.1 Hz, 1H), 4.59 (t, J = 12.1 Hz, 2H), 4.48 (d, J = 12.1 Hz, 1H), 4.43 (s, 2H), 4.15 – 4.10 (m, 1H), 3.77 (dd, J = 10.6, 4.8 Hz, 1H), 3.73 (dd, J = 10.6, 3.5 Hz, 1H), 3.66 – 3.60 (m, 2H), 3.43 (t, J = 4.7 Hz, 1H), 3.07 (dt, J = 8.2, 5.3 Hz, 1H), 2.36 (s, 3H), 1.92 (s, 3H), 1.40 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 206.8, 143.1, 138.3, 138.3, 137.8, 137.0, 129.2, 128.4, 128.4, 128.4, 127.9, 127.9, 127.8, 127.7, 127.6, 124.9, 98.7, 83.5, 76.4, 73.4, 72.7, 72.5, 72.3, 69.3, 62.6, 45.0, 31.8, 29.7, 24.3, 21.0; ESI-HRMS: m/z calcd for C₃₉H₄₂NaO₆[M+Na][†]: 629.2874; found: 629.2891.

(2S, 3S, 3aR, 4R, 5S, 6R, 7aS) - 3 - acetyl - 4, 5 - bis(benzyloxy) - 6 - [(benzyloxy)methyl] - (benzyloxy)methyl] - (benzyloxy)methyl - (benzyloxy)methyll - (benzyloxy)methyl

2-methyl-2-(4-chlorophenyl)hexahydrofuro[2,3-b]pyran (3bc)

Compound **3bc** was prepared according to Method A using (47.3 mg, 0.1 mmol) cyclopropanated sugars **1b** and ketone **2c** (53.5 μ L, 0.4 mmol), after purified by column chromatography on silica gel (ethyl acetate/ petroleum ether = 1:9), afforded the desired product **3bc** (51.4 mg, 0.082 mmol, 82%) as colorless syrup. [α]_D²⁰ +40.0 (c 0.13, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.43 (d, J = 8.5 Hz, 2H), 7.35 – 7.28 (m, 11H), 7.24 (dd, J = 12.4, 4.6 Hz, 4H), 7.11 (dd, J = 6.2, 2.8 Hz, 2H), 5.67 (d, J = 5.2 Hz, 1H), 4.59 (q, J = 12.1 Hz, 3H), 4.49 (d, J = 12.2 Hz, 1H), 4.43 (s, 2H), 4.12 – 4.08 (m, 1H), 3.77 (dd, J = 10.5, 5.1 Hz, 1H), 3.72 (dd, J = 10.5, 3.7 Hz, 1H), 3.62 (dd, J = 6.6, 4.8 Hz, 1H), 3.56 (d, J = 8.3 Hz, 1H), 3.39 (t, J = 4.8 Hz, 1H), 3.02 (dt, J = 9.5, 5.2 Hz, 1H), 1.91 (s, 3H), 1.38 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 206.4, 144.8, 138.2, 137.7, 133.3, 128.7, 128.5, 128.4, 128.4, 127.9, 127.9, 127.8, 127.6, 126.6, 98.6, 83.2, 76.4, 76.1, 73.5, 72.7, 72.6, 72.4, 69.1, 62.4, 45.1, 31.8, 29.7, 24.3; ESI-HRMS: m/z calcd for C₃₈H₃₉ClNaO₆[M+Na][†]: 649.2327; found: 649.2325.

(2S,3S,3aR,4R,5S,6R,7aS)-3-acetyl-4,5-bis(benzyloxy)-6-[(benzyloxy)methyl]-

2-methyl-2-(4-bromophenyl)hexahydrofuro[2,3-b]pyran (3bd)

Compound **3bd** was prepared according to Method A using (47.3 mg, 0.1 mmol) cyclopropanated sugars **1b** and ketone **2d** (81.2 mg , 0.4 mmol), after purified by column chromatography on silica gel (ethyl acetate/ petroleum ether = 1:9), afforded the desired product **3bd** (55.0 mg, 0.082 mmol, 82%) as colorless syrup. [α]_D²⁰ +35.0 (c 0.29, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.45 (d, J = 8.4 Hz, 2H), 7.37 (d, J = 8.4 Hz, 2H), 7.35 – 7.26 (m, 11H), 7.22 (d, J = 7.0 Hz, 2H), 7.12 (s, 2H), 5.67 (d, J = 5.2 Hz, 1H), 4.63 – 4.57 (m, 3H), 4.48 (d, J = 12.2 Hz, 1H), 4.44 (s, 2H), 4.12 – 4.07 (m, 1H), 3.77 (dd, J = 10.3, 5.1 Hz, 1H), 3.74 – 3.69 (m, 1H), 3.64 – 3.60 (m, 1H), 3.55 (d, J = 8.1 Hz, 1H), 3.39 (t, J = 4.7 Hz, 1H), 3.01 (dt, J = 8.4, 5.3 Hz, 1H), 1.92 (s, 3H), 1.37 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 206.4, 145.3, 138.2, 137.7, 131.7, 128.5, 128.4, 128.4, 127.9, 127.9, 127.8, 127.6, 126.9, 121.4, 98.6, 83.3, 76.4, 76.1, 73.5, 72.7, 72.7, 72.4, 69.0, 62.3, 45.2, 31.9, 29.7, 24.3; ESI-HRMS: m/z calcd for C₃₈H₃₉BrNaO₆[M+Na]⁺: 693.1822; found: 693.1830.

(3S,3aR,4R,5S,6R,7aS)-3-acetyl-4,5-bis(benzyloxy)-6-[(benzyloxy)methyl]-

2,2-di-methylhexahydrofuro[2,3-b]pyran (3bj)

Compound **3bj** was prepared according to Method B using (47.3 mg, 0.1 mmol) cyclopropanated sugars **1b** and acetone **2j** (74.2 μ L, 1.0 mmol), after purified by column chromatography on silica gel (ethyl acetate/ petroleum ether = 1:6), afforded the desired product **3bj** (48.8 mg, 0.092 mmol, 92%) as colorless syrup. [α]_D²⁰ +47.8 (c 0.32, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.36 – 7.27 (m, 13H), 7.15 – 7.12 (m, 2H), 5.48 (d, J = 5.9 Hz, 1H), 4.65 (d, J = 12.2 Hz, 1H), 4.59 (dd, J = 12.3 Hz, 2H), 4.53 (d, J = 12.1 Hz, 1H), 4.35 (s, 2H), 3.95 – 3.90 (m, 1H), 3.68 (dd, J = 4.2, 2.4 Hz, 2H), 3.65 (d, J = 7.2 Hz, 1H), 3.52 (t, J = 3.2 Hz, 1H), 3.29 (d, J = 10.1 Hz, 1H), 3.22 – 3.17 (m, 1H), 2.06 (s, 3H), 1.55 (s, 3H), 1.03 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 205.6, 138.3, 138.2, 137.8, 128.4, 128.4, 128.3, 128.1, 127.9, 127.8, 127.5, 97.9, 80.8, 76.0, 75. 5, 73.4, 72.1,

71.5, 71.3, 69.5, 61.2, 43.1, 31.1, 29.8, 29.7, 24.4; ESI-HRMS: m/z calcd for $C_{33}H_{38}NaO_6[M+Na]^+$: 553.2561; found: 553.2550.

(2R,3S,3aR,4R,5S,6R,7aS)-3-acetyl-4,5-bis(benzyloxy)-6-[(benzyloxy)methyl]-

2-ethyl-2-methylhexahydrofuro[2,3-b]pyran (3bk)

Compound **3bk** was prepared according to Method A using (47.3 mg, 0.1 mmol) cyclopropanated sugars **1b** and 2-butanone **2k** (36.2 μ L, 0.4 mmol), after purified by column chromatography on silica gel (ethyl acetate/ petroleum ether = 1:6), afforded the desired product **3bk** (45.2 mg, 0.083 mmol, 83%) as colorless syrup. [α]_D²⁰ +9.0 (c 0.37, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.38 – 7.26 (m, 13H), 7.16 (d, J = 7.7 Hz, 2H), 5.47 (d, J = 5.7 Hz, 1H), 4.64 (t, J = 10.1 Hz, 2H), 4.59 (d, J = 12.1 Hz, 1H), 4.54 (d, J = 12.1 Hz, 1H), 4.40 (s, 2H), 3.97 (dt, J = 8.4, 4.4 Hz, 1H), 3.72 – 3.66 (m, 2H), 3.63 (dd, J = 6.9, 3.2 Hz, 1H), 3.52 (t, J = 3.9 Hz, 1H), 3.29 (d, J = 9.3 Hz, 1H), 3.14 – 3.09 (m, 1H), 2.02 (s, 3H), 1.78 (q, J = 7.4 Hz, 2H), 1.26 (s, 3H), 0.99 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 206.1, 138.3, 138.3, 137.9, 128.5, 128.4, 128.3, 128.1, 127.8, 127.8, 127.5, 97.8, 83.0, 76.1, 76.0, 73.4, 72.3, 71.8, 71.6, 69.4, 59.1, 43.5, 35.0, 31.9, 31.1, 29.7, 22.0, 8.5; ESI-HRMS: m/z calcd for C₃₄H₄₀NaO₆[M+Na]⁺: 567.2717; found: 567.2733.

(2R,3S,3aR,4R,5S,6R,7aS)-3-acetyl-4,5-bis(benzyloxy)-6-[(benzyloxy)methyl]-

2-cyclopropyl-2-methyl-hexahydrofuro[2,3-b]pyran (3bm)

Compound **3bm** was prepared according to Method A using (47.3 mg, 0.1 mmol) cyclopropanated sugars **1b** and **2m** (38.0 μ L, 0.4 mmol), after purified by column chromatography on silica gel (ethyl acetate/ petroleum ether = 1:9), afforded the desired product **3bm** (52.8 mg, 0.095 mmol, 95%) as colorless syrup. [α]_D²⁰ +13.0 (c 0.26, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.36 – 7.25 (m, 13H), 7.15 (d, J = 6.4 Hz, 2H), 5.43 (d, J = 5.9 Hz, 1H), 4.65 (d, J = 12.2 Hz, 1H), 4.59 (d, J = 8.7 Hz, 1H), 4.57 (d, J = 8.6 Hz, 1H), 4.54 (d, J = 12.1 Hz, 1H), 4.36 (s, 2H), 3.96 (dt, J = 8.7, 4.5 Hz, 1H), 3.67 (d, J = 4.4 Hz, 2H), 3.61 (dd, J = 7.2, 1.6 Hz, 1H), 3.53 (t, J = 3.1 Hz, 1H), 3.49 (d,

J = 10.5 Hz, 1H), 3.23 - 3.17 (m, 1H), 2.12 (s, 3H), 1.20 - 1.13 (m, 1H), 0.95 (s, 3H), 0.88 (t, J = 6.9 Hz, 1H), 0.74 - 0.67 (m, 1H), 0.54 - 0.44 (m, 2H); ^{13}C NMR (150 MHz, CDCl₃) δ 206.0, 138.3, 138.3, 137.9, 128.4, 128.4, 128.3, 128.0, 127.8, 127.8, 127.5, 97.4, 81.9, 75.9, 75.5, 73.4, 72.0, 71.6, 71.5, 69.6, 61.6, 42.9, 31.3, 29.7, 21.6, 21.4, 2.8, 1.2; ESI-HRMS: m/z calcd for $C_{35}H_{40}\text{NaO}_{6}\text{[M+Na]}^{+}$: 579.2717; found: 579.2721.

(2S,3S,3aS,4R,5R,6aR)-3-acetyl-4-(benzyloxy)-5-[(benzyloxy)methyl]-2-methyl-2-phenyl-hexahydrofuro[2,3-b]furan (3ca)

Compound **3ca** was prepared according to Method A using (35.2 mg, 0.1 mmol) cyclopropanated sugars **1c** and ketone **2a** (47.2 μ L, 0.4 mmol), after purified by column chromatography on silica gel (ethyl acetate/ petroleum ether = 1:9), afforded the desired product **3ca** (41.1 mg, 0.087 mmol, 87%) as colorless syrup. [α]_D²⁰ -29.2 (c 0.27, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.57 (d, J = 7.3 Hz, 2H), 7.39 – 7.22 (m, 11H), 7.14 (d, J = 6.6 Hz, 2H), 5.67 (d, J = 5.0 Hz, 1H), 4.63 (d, J = 12.1 Hz, 1H), 4.57 (d, J = 12.1 Hz, 1H), 4.40 (d, J = 11.4 Hz, 1H), 4.36 – 4.31 (m, 3H), 3.86 (dd, J = 10.3, 4.1 Hz, 1H), 3.82 (dd, J = 13.8, 8.7 Hz, 1H), 3.75 (dd, J = 10.2, 5.6 Hz, 2H), 1.77 (s, 3H), 1.44 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 206.1, 145.1, 138.3, 137.6, 128.6, 128.4, 127.8, 127.7, 127.6, 127.6, 127.5, 127.0, 125.7, 106.1, 88.8, 79.8, 78.0, 73.67, 73.43, 69.8, 62.1, 50.5, 31.6, 29.7, 22.9; ESI-HRMS: m/z calcd for C₃₀H₃₂NaO₅[M+Na]⁺: 495.2142; found: 495.2144.

(2S, 3S, 3aS, 4R, 5R, 6aR) - 3 - acetyl - 4 - (benzyloxy) - 5 - [(benzyloxy)methyl] - 2 - methyl - 2 - (4 - tolyl) - bexahydrofuro [2, 3-b] furan (3cb)

Compound **3cb** was prepared according to Method A using (35.2 mg, 0.1 mmol) cyclopropanated sugars **1c** and ketone **2b** (56.2 μ L, 0.4 mmol), after purified by column chromatography on silica gel (ethyl acetate/ petroleum ether = 1:9), afforded the desired product **3cb** (38.9 mg, 0.080 mmol,

80%) as colorless syrup. [α]_D²⁰ -133.9 (c 0.12, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.45 (d, J = 8.2 Hz, 2H), 7.36 – 7.27 (m, 8H), 7.14 (d, J = 7.8 Hz, 4H), 5.65 (d, J = 5.0 Hz, 1H), 4.64 (d, J = 12.0 Hz, 1H), 4.57 (d, J = 12.1 Hz, 1H), 4.40 (d, J = 11.4 Hz, 1H), 4.32 (dd, J = 8.9, 6.0 Hz, 3H), 3.86 (dd, J = 10.3, 4.0 Hz, 1H), 3.84 – 3.79 (m, 1H), 3.76 (dd, J = 10.4, 6.0 Hz, 1H), 3.73 (d, J = 10.0 Hz, 1H), 2.35 (s, 3H), 1.77 (s, 3H), 1.42 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 206.2, 142.2, 138.3, 137.6, 137.3, 129.0, 128.4, 128.3, 127.8, 127.8, 127.6, 127.5, 125.6, 106.0, 88.7, 79.7, 78.0, 73.6, 73.4, 69.9, 62.2, 50.3, 31.6, 29.7, 22.9, 21.0; ESI-HRMS: m/z calcd for $C_{31}H_{34}NaO_{5}[M+Na]^{+}$: 509.2298; found: 509.2304.

(2S,3S,3aS,4R,5R,6aR)-3-acetyl-4-(benzyloxy)-5-[(benzyloxy)methyl]-2-methyl-2-(4-bromophenyl)hexahydrofuro[2,3-b]furan (3cd)

Compound **3cd** was prepared according to Method A using (35.2 mg, 0.1 mmol) cyclopropanated sugars **1c** and ketone **2d** (81.2 mg , 0.4 mmol), after purified by column chromatography on silica gel (ethyl acetate/ petroleum ether = 1:9), afforded the desired product **3cd** (42.9 mg, 0.078 mmol, 78%) as colorless syrup. [α]_D²⁰ -70.2 (c 0.17, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.43 (s, 2H), 7.33 – 7.26 (m, 10H), 7.13 (d, J = 6.8 Hz, 2H), 5.64 (d, J = 4.9 Hz, 1H), 4.59 (d, J = 12.0 Hz, 1H), 4.55 (d, J = 11.9 Hz, 1H), 4.40 (d, J = 11.4 Hz, 1H), 4.35 – 4.27 (m, 4H), 3.82 (dd, J = 10.3, 4.3 Hz, 1H), 3.81 – 3.76 (m, 1H), 3.72 (d, J = 9.9 Hz, 1H), 3.69 (dd, J = 10.3, 6.0 Hz, 1H), 1.77 (s, 3H), 1.40 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 205.8, 144.5, 138.1, 137.5, 131.4, 128.4, 127.9, 127.8, 127.7, 127.6, 127.6, 121.6, 106.1, 88.5, 79.7, 77.9, 73.8, 73.5, 69.6, 61.8, 50.6, 31.7, 23.0; ESI-HRMS: m/z calcd for C₃₀H₃₁BrNaO₅[M+Na]⁺: 573.1247; found: 573.1258.

(2S,3S,3aS,4R,5R,6aR)-3-acetyl-4-(benzyloxy)-5-[(benzyloxy)methyl]-2-ethyl-2-phenyl-bexahydrofuro[2,3-b]furan (3cf)

Compound 3cf was prepared according to Method A using (35.2 mg, 0.1 mmol) cyclopropanated

sugars **1c** and ketone **2f** (54.3 μL, 0.4 mmol), after purified by column chromatography on silica gel (ethyl acetate/ petroleum ether = 1:9), afforded the desired product **3cf** (36.5 mg, 0.075 mmol, 75%) as colorless syrup. [α]_D²⁰-23.0 (c 0.37, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.49 (d, J = 7.7 Hz, 2H), 7.37 – 7.24 (m, 11H), 7.12 (d, J = 6.6 Hz, 2H), 5.69 (d, J = 5.2 Hz, 1H), 4.64 (d, J = 12.1 Hz, 1H), 4.55 (d, J = 12.0 Hz, 1H), 4.40 (d, J = 11.5 Hz, 1H), 4.38 – 4.34 (m, 1H), 4.32 (dd, J = 13.3, 4.7 Hz, 2H), 3.83 (dd, J = 10.4, 4.2 Hz, 1H), 3.81 – 3.76 (m, 1H), 3.74 (dd, J = 10.4, 6.7 Hz, 1H), 3.64 (d, J = 9.8 Hz, 1H), 1.87 (s, 3H), 1.83 (dt, J = 14.6, 7.3 Hz, 1H), 1.68 (dq, J = 14.5, 7.2 Hz, 1H), 0.76 (t, J = 7.3 Hz, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 206.5, 143.3, 138.3, 137.5, 128.4, 127.8, 127.7, 127.6, 127.5, 127.3, 125.8, 106.1, 91.3, 80.0, 78.1, 73.5, 73.4, 70.1, 62.4, 50.9, 32.3, 27.6, 7.7; ESI-HRMS: m/z calcd for C₃₁H₃₄NaO₅[M+Na][†]: 509.2298; found: 509.2305.

(2S,3S,3aS,4R,5R,6aR)-3-acetyl-4-(benzyloxy)-5-[(benzyloxy)methyl]-2-(furan-2-yl) 2-methyl-hexahydrofuro[2,3-b]furan (3cg)

Compound **3cg** was prepared according to Method A using (35.2 mg, 0.1 mmol) cyclopropanated sugars **1c** and ketone **2g** (44.5 mg, 0.4 mmol), after purified by column chromatography on silica gel (ethyl acetate/ petroleum ether = 1:9), afforded the desired product **3cg** (28.7 mg, 0.062 mmol, 62%) as colorless syrup. [α] $_{\rm D}^{20}$ -40.0 (c 0.09, CHCl₃); 1 H NMR (600 MHz, CDCl₃) δ 7.35 – 7.28 (m, 9H), 7.20 (d, J = 7.2 Hz, 2H), 6.36 (d, J = 3.2 Hz, 1H), 6.34 (d, J = 1.7 Hz, 1H), 5.64 (d, J = 5.6 Hz, 1H), 4.69 (d, J = 12.2 Hz, 1H), 4.58 (d, J = 12.2 Hz, 1H), 4.44 (d, J = 8.4 Hz, 1H), 4.40 – 4.36 (m, 3H), 4.14 (d, J = 9.3 Hz, 1H), 3.97 (d, J = 5.3 Hz, 2H), 3.86 (td, J = 8.6, 5.8 Hz, 1H), 1.80 (s, 3H), 1.36 (s, 3H); 13 C NMR (150 MHz, CDCl₃) δ 204.8, 155.0, 142.6, 138.6, 137.7, 128.4, 128.3, 127.8, 127.7, 127.5, 127.4, 127.4, 110.4, 107.9, 106.4, 82.6, 80.6, 78.1, 73.5, 73.2, 70.1, 58.3, 47.3, 30.3, 21.3; ESI-HRMS: m/z calcd for C_{28} H₃₀NaO₆[M+Na] $^{+}$: 485.1935; found: 485.1951.

Spirocyclic compound 3ci

Compound **3ci** was prepared according to Method A using (35.2 mg, 0.1 mmol) cyclopropanated sugars **1c** and ketone **2i** (41.9 μ L, 0.4 mmol), after purified by column chromatography on silica gel (ethyl acetate/ petroleum ether = 1:9), afforded the desired product **3ci** (39.6 mg, 0.088 mmol, 88%) as colorless syrup. [α]_D²⁰ -10.0 (c 0.32, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.36 – 7.27 (m, 8H), 7.19 (d, J = 7.4 Hz, 2H), 5.51 (d, J = 5.2 Hz, 1H), 4.61 (s, 1H), 4.60 (s, 1H), 4.42 (d, J = 11.7 Hz, 1H), 4.33 (d, J = 11.6 Hz, 1H), 4.27 (d, J = 5.2 Hz, 2H), 3.80 (dd, J = 9.9, 2.5 Hz, 1H), 3.76 – 3.71 (m, 1H), 3.69 (td, J = 8.5, 4.5 Hz, 1H), 3.37 (d, J = 9.1 Hz, 1H), 2.06 (s, 3H), 1.87 (d, J = 13.1 Hz, 1H), 1.77 – 1.70 (m, 1H), 1.58 (s, 4H), 1.48 (d, J = 13.4 Hz, 1H), 1.07 (d, J = 13.0 Hz, 1H), 0.88 (d, J = 6.5 Hz, 1H), 0.79 (d, J = 13.4 Hz, 1H); ¹³C NMR (150 MHz, CDCl₃) δ 205.9, 138.3, 137.8, 128.4, 128.3, 127.8, 127.8, 127.5, 127.4, 105.8, 86.5, 79.9, 78.2, 73.4, 73.3, 69.5, 60.6, 48.7, 38.8, 33.4, 31.5, 29.7, 25.4, 23.2, 21.5; ESI-HRMS: m/z calcd for C₂₈H₃₄NaO₅[M+Na]⁺: 473.2298; found: 473.2304.

(3S,3aS,4R,5R,6aR)-3-acetyl-4-(benzyloxy)-5-[(benzyloxy)methyl]-2,2-di-methyl-hexahydrofuro[2,3-b]furan (3cj)

Compound **3cj** was prepared according to Method B using (35.2 mg, 0.1 mmol) cyclopropanated sugars **1c** and acetone **2j** (74.2 μ L, 1.0 mmol), after purified by column chromatography on silica gel (ethyl acetate/ petroleum ether = 1:9), afforded the desired product **3cj** (34.0 mg, 0.083 mmol, 83%) as colorless syrup. [α]_D²⁰ -6.1 (c 0.16, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.36 – 7.26 (m, 8H), 7.20 (d, J = 7.0 Hz, 2H), 5.50 (d, J = 5.4 Hz, 1H), 4.62 (d, J = 12.0 Hz, 1H), 4.58 (d, J = 12.1 Hz, 1H), 4.43 (d, J = 11.6 Hz, 1H), 4.35 (d, J = 11.6 Hz, 1H), 4.31 – 4.25 (m, 2H), 3.82 (dd, J = 10.3, 3.7 Hz, 1H), 3.75 – 3.69 (m, 2H), 3.49 (d, J = 9.1 Hz, 1H), 2.05 (s, 3H), 1.52 (s, 3H), 1.01 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 205.7, 138.3, 137.7, 128.4, 128.3, 127.9, 127.8, 127.6, 127.4, 106.1, 85.0, 80.0, 78.1, 73.5, 73.3, 69.5, 60.1, 49.1, 30.9, 29.8, 29.7, 24.7; ESI-HRMS: m/z calcd for $C_{25}H_{30}NaO_{5}[M+Na]^{+}$: 433.1985; found: 433.1994.

Selected IR data for the products:


- a. **3ah**: IR (KBr) v 3423.1, 2918.7, 2869.9, 1715.5, 1615.2, 1585.4, 1483.7, 1454.0, 1358.2, 1320.0, 1186.7, 1125.9, 1098.6, 1062.5, 1027.3, 969.1, 920.8, 751.8, 698.1.
- b. **3cb**: IR (neat) v 2920.0, 2867.9, 1710.4, 1514.1, 1596.4, 1453.6, 1378.8, 1352.8, 1244.6, 1120.5, 1104.1, 1053.2, 1028.1, 819.2, 737.7, 698.3.
- c. **3cd**: IR (neat) v 2916.5, 2867.9, 1711.6, 1590.7, 1495.0, 1453.7, 1397.7, 1356.4, 1243.2, 1103.3, 1083.1, 1047.2, 1007.8, 912.2, 829.4, 738.0, 698.6.

The stereochemistry of the products

The configuration of the products was unambiguously assigned by extensively studied the NMR and NOE of the products. The coupling constants between H_{7a} and H_{3a} ($J_{H7a, H3a} = 4.3 - 4.5$ Hz for the products from compound $\mathbf{1a}$, $J_{H7a, H3a} = 5.2 - 5.9$ Hz for the products from compound $\mathbf{1b}$ and $J_{H6a, H3a} = 4.9 - 5.6$ Hz for the products from compound $\mathbf{1c}$) showed convincingly that the fused ring system have a *cis*-bicyclic configuration, the stereochemistry of C2 and C3 position were determined using the NOE difference spectra (**Scheme S1**).

For the stereochemistry of the 3c series compounds, the coupling constants between H_{6a} and $H_{3a}(J_{H6a, H3a} = 4.9 - 5.6 \text{ Hz})$ manifested convincingly that the fused ring system have a cis-bicyclic configuration. The stereochemistry of C3 position was determined by coupling constants between H_{3a} and $H_3(J_{H3, H3a} = 9.1 - 10.0 \text{ Hz})$, which demonstrated the cis- correlation between them (Proton proton coupling constants in a bis-THF system: $J_{H3, H3a} > 7.0 \text{ Hz}$ for a cis-stereochemistry, $J_{H3, H3a} = 0 \text{ Hz}$ for a trans-stereochemistry, I_{11} The NOE between I_{11} and I_{12} for a I_{12} manifested the I_{13} correlation of among them. I_{14} and I_{14}

Scheme S1 Key NOEs of Perhydrofuro[2,3-b]pyran Derivatives.



References:

1: (a) L. Bueno-Perez, J. Li, D. D. Lantvit, L. Pan, T. N. Ninh, H. B. Chai, D. D. Soejarto, S. M. Swanson, D. M. Lucas and A. D. Kinghorn, *J. Nat. Prod.*, 2013, **76**, 1498; (b) M. C. Pirrung, and Y. R. Lee, *J. Am. Chem. Soc.*,1995, **117**, 4814. (c) L. C. Chang, D. Chávez, L. L. Song, N. R. Farnsworth, J. M. Pezzuto and A. D. Kinghorn, *Org. lett.*, 2000, **2**, 515; (d) A. M. Abou-Douh, C. Ito, R. A. Toscano, N. Y. El-Baga, E. A. El-Khrisy and H. Furukawa, *Zeitschrift fur Naturforschung B*, 2005, **60**, 458; (e) E. V. Rao and N. R. Raju, *Phytochemistry*, 1984, **23**. 2339; (f) V. Lucchini, M. Prato, G. Scorrano, M. Stivanello and G. Valle, *J. Chem. Soc., Perkin Trans.*, *2*, 1992, 259. (g) A. K. Ghosh, C. X. Xu, K. V. Rao, A. Baldridge, J. Agniswamy, Y. F. Wang and H. Mitsuya, *ChemMedChem*, 2010, **5**, 1850.

(a) F. Alonso, M. Rodríguez - Fernández, D. Sánchez, M. Yus, Eur. J. Org. Chem., 2011, 6459;
(b) F. Alonso, M. Rodríguez-Fernandez, D. Sanchez, M. Yus, Synthesis, 2010, 3013.